Streetbeat News

EIGR

Eiger BioPharmaceuticals Inc

http://www.eigerbio.com/

CEO

David Cory

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Open

1.90

Mkt cap

2.6M

Volume

130K

High

1.90

P/E Ratio

-0.03

52-wk high

43.35

Low

1.73

Div yield

N/A

52-wk low

1.10

In Thursday's after-market session, several healthcare stocks showed notable movements. Orgenesis, AN2 Therapeutics, GRI Bio, NuCana, Stoke Therapeutics, and Candel Therapeutics were among the gainers, with increases ranging from 4.99% to 8.5%. On the downside, Acorda Therapeutics, Aesthetic Medical Intl, Eiger BioPharmaceuticals, Coeptis Therapeutics, iSpecimen, and WAVE Life Sciences experienced declines between 4.96% and 8.9%. These movements reflect the dynamic nature of the healthcare sector in the stock market.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 8:31 pm

Health care stocks experienced significant movements in Thursday's intraday session. Candel Therapeutics, TC BioPharm, Eiger BioPharmaceuticals, Macrogenics, Barinthus Biotherapeutics, and Curis saw notable gains, with increases ranging from 24.62% to 64.3%. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, Inotiv, Universe Pharmaceuticals, Kintara Therapeutics, and Carmell faced declines, with decreases ranging from 12.85% to 80.2%. The movements were attributed to various factors, including earnings releases and market dynamics.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:31 pm

Flora Growth Corp. (NASDAQ:FLGC) shares fell by 20.2% in pre-market trading following the announcement of a proposed underwritten public offering of common shares. Other stocks also showed significant movement in pre-market trading, with HWH International Inc. (NASDAQ:HWH) rising 175% and Casa Systems, Inc. (NASDAQ:CASA) declining 20.8%. Various factors influenced these movements, including earnings reports, merger agreements, and public offerings.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 11:58 am

Eiger Biopharmaceuticals received a notice from Nasdaq on April 2 about the delisting of its common stock, which is expected to start trading on the Over-the-Counter market on April 11, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 8:49 pm

In Wednesday's after-market session, several healthcare stocks showed notable movements. Aesthetic Medical Intl, Kineta, Simulations Plus, Bolt Biotherapeutics, Eiger BioPharmaceuticals, and Kodiak Sciences were among the gainers, with Simulations Plus and Kodiak Sciences releasing their Q2 and Q4 earnings reports, respectively. On the losing side, Connect Biopharma Holdings, Acorda Therapeutics, Innate Pharma, Qilian Intl Holding Group, Universe Pharmaceuticals, and Helius Medical Technologies experienced declines, with Acorda Therapeutics and Helius Medical Technologies also releasing their Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 8:31 pm

Nuvve Holding Corp. shares plummeted by approximately 30% after reporting Q4 financial results significantly below market expectations. Other stocks experienced notable movements, with Vast Renewables and CXApp Inc. leading the gainers, while Eiger BioPharmaceuticals and Andretti Acquisition Corp. were among the biggest losers.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 6:31 pm

Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) filed for Chapter 11 bankruptcy and announced a 'stalking horse' agreement to sell Zokinvy to Sentynl Therapeutics for up to $26.0 million. The sale is subject to court approval and potential competing bids. Eiger aims to sell most of its assets and wind down operations. Previously, Eiger and AnGes Inc. received marketing approval for Zokinvy for progeria. EIGR shares dropped 73.2% to $1.34.

Portfolio Pulse from Vandana Singh

April 01, 2024 | 5:43 pm

In Monday's intraday session, health care stocks saw significant movements. Sunshine Biopharma, Xilio Therapeutics, Akanda, Mesoblast, Brainstorm Cell, and Adagene were among the gainers with notable percentage increases in their stock prices. On the downside, Eiger BioPharmaceuticals, Disc Medicine, AEON Biopharma, Biora Therapeutics, Sharecare, and ENDRA Life Sciences experienced substantial declines. The movements were attributed to various factors including quarterly earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:31 pm

Eiger BioPharmaceuticals has filed for voluntary Chapter 11 protection, leading to a decrease in its share prices.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 3:22 pm

Eiger BioPharmaceuticals' stock resumed trading after a circuit breaker halt, experiencing a significant drop of 55.6%.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 3:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.